Value in Health

• 

  Publication Venue For

  • Cost-Effective Analysis of Dual-Energy Computed Tomography for the Diagnosis of Occult Hip Fractures Among Older Adults..  24:1754-1762. 2021
  • Cost-Effectiveness of the Wellness Incentives and Navigation (WIN) Program.  24:361-368. 2021
  • Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group..  23:831-841. 2020
  • Current Policy and Practice for Value-Based Pricing..  22:S4-S6. 2019
  • Does Birthplace Independently Predict Human Papillomavirus Vaccine Initiation?.  19:A221-A221. 2016
  • Race, Sex, And Geographic Variations in Depression among Cancer Patients in the United States.  19:A20-A20. 2016
  • Patients’ And Physicians’ Time Trade-Off Preferences For Adverse Outcomes Associated With Metastatic Colorectal Cancer Treatments.  18:A9-A9. 2015
  • Rapid Acquisition of Data on The Patient Perspective In Rheumatoid Arthrtis Through A Digital Portal.  18:A165-A165. 2015
  • What are people willing to pay for whole genome sequencing information?.  18:A285-A286. 2015
  • The effects of total knee arthroplasty on physical functioning and health among the under age 65 population..  17:605-610. 2014
  • HEALTH CARE SPENDING PATTERNS IN HIGH RESOURCE PATIENTS.  17:A148-A148. 2014
  • Physicians’ Preferences for Bone Metastases Treatments in Canada.  17:A93-A93. 2014
  • Patients at the Center of Regulatory Decisions: Using Stated-Preference Data to Help Regulators Answer Difficult Questions.  16:A387-A387. 2013
  • Psoriasis Patients’ Tolerance for Therapeutic Risks in Return for Symptom Improvement in the United Kingdom.  16:A508-A508. 2013
  • Which Cystic Fibrosis Inhaled Antibiotic Medicine Features Matter Most to Adult Patients and Parents of Pediatric Patients?.  16:A722-A722. 2013
  • Challenges in assessing the impact of hyponatremia management on length of stay: Interim results from a global, multi-center, prospective, observational registry of hospitalized hypervolemic and euvolemic hyponatremic patients.  16:A18-A18. 2013
  • Getting To Better Value From Medical Devices: Reimbursement And Pricing Policies In Europe And The United States.  16:A249-A249. 2013
  • Patient And Physician Preferences In The United States For Benefits And Risks Of Anticoagulant Use In Atrial Fibrillation – Results From A Conjoint-Analysis Study.  16:A11-A11. 2013
  • Stated time-allocation, adherence, and health-outcome tradeoff preferences in cystic fibrosis households.  16:A26-A26. 2013
  • A MAXIMUM LIKELIHOOD SIMULATION TECHNIQUE FOR ESTIMATING ADVERSE EVENT RATES FROM PUBLISHED TRIALS.  15:A487-A487. 2012
  • JAPANESE PATIENTS AND PHYSICIANS PREFERENCES FOR ANTICOAGULANTS USE IN ATRIAL FIBRILLATION - RESULTS FROM A CONJOINT-ANALYSIS STUDY.  15:A380-A380. 2012
  • PCV26 Lifetime Cost-Effectiveness Analysis of Ticagrelor in Patients With Acute Coronary Syndromes Based on the Plato Trial: A Singapore Health Care Perspective.  15:A632-A633. 2012
  • PDB64 The Avoidance of Weight Gain is Important for Oral Type 2 Diabetes Treatments in Sweden and Germany: A Patient Preference Study.  15:A505-A505. 2012
  • PMD46 Doctor Knows Best: The Effect of Yea-Saying Bias on Willingness to Pay in Choice-Format Conjoint-Analysis Studies.  15:A70-A70. 2012
  • PMS46 Patient Trade-Offs Between Frequency and Duration of Biologic Treatments for Rheumatoid Arthritis.  15:A42-A42. 2012
  • PND35 Fictitious Preferences or Felicitous Recoding? Conjoint Respondents Who Make Sense of Nonsensical Questions.  15:A147-A147. 2012
  • PND36 Structured Benefit-Risk Assessment of Triptan Treatments Using Patient-Preference Data.  15:A147-A147. 2012
  • Incorporating indirect costs into a cost-benefit analysis of laparoscopic adjustable gastric banding..  15:299-304. 2012
  • Availability, health-care costs, and utilization patterns of biologics in Taiwan..  15:S35-S42. 2012
  • CHARACTERISTICS INFLUENCING JAPANESE ATRIAL FIBRILLATION PATIENTS PREFERENCES FOR ANTICOAGULANTS USE.  15:A380-A381. 2012
  • PDB58 How Much Do Patients with Type 2 Diabetes Value Improvements in Dosing Convenience? Results from a Conjoint Study.  14:A482-A482. 2011
  • PHP125 Clinical Trial Learning Curves May Impact Both Clinical and Economic Outcomes, and Influence Health Technology Assessment and Reimbursement Decision Making.  14:A356-A356. 2011
  • PIN89 Do Patients and Physicians Have Similar Preferences Chronic Hepatitis B Treatment Outcomes in Turkey?.  14:A282-A282. 2011
  • PSY38 Estimating Healthy-Time Equivalents for Migraine Treatment Outcomes from Conjoint Analysis Measures of Patient Preferences.  14:A417-A417. 2011
  • PHP74 CLINICAL TRIAL LEARNING CURVES AFFECT OUTCOMES MEASUREMENT, PATIENT SAFETY AND TRIAL SUCCESS: CONTRIBUTING FACTORS AND A POTENTIAL SOLUTION IN CLINICAL TRIAL SIMULATION.  14:A24-A25. 2011
  • PIN40 DO PATIENTS AND PHYSICIANS HAVE SIMILAR PREFERENCES FOR HEALTH CARE DECISIONS INVOLVING UNCERTAIN OUTCOMES FOR CHRONIC HEPATITIS B IN GERMANY AND TURKEY?.  14:A121-A121. 2011
  • PMD18 THE COST-EFFECTIVENESS OF INITIATING SENSOR-AUGMENTED PUMP THERAPY VERSUS MULTIPLE DAILY INJECTIONS OF INSULIN IN ADULTS WITH TYPE 1 DIABETES: EVALUATING A TECHNOLOGY IN EVOLUTION.  14:A82-A82. 2011
  • PMD29 PATIENT TIME AND INDIRECT COSTS ASSOCIATED WITH SENSOR-AUGMENTED INSULIN PUMP THERAPY IN TYPE 1 DIABETES.  14:A84-A84. 2011
  • PMD34 PREFERENCES FOR GENETIC TESTING TO ASSESS COLON-CANCER RISKS.  14:A84-A84. 2011
  • PSY4 TRENDS IN HYPONATREMIA MANAGEMENT AND ASSOCIATED OUTCOMES IN HOSPITAL SETTINGS: INTERIM RESULTS FROM AN OBSERVATIONAL, PROSPECTIVE, MULTI-CENTER, GLOBAL REGISTRY IN HOSPITALIZED PATIENTS.  14:A59-A59. 2011
  • BL2 PATIENT PREFERENCES FOR BIOLOGIC AGENTS IN RHEUMATOID ARTHRITIS: A DISCRETE CHOICE EXPERIMENT.  13:A243-A243. 2010
  • PMS50 PATIENTS' STATED HEALTH-OUTCOME PREFERENCES FOR CONFOUNDED PATIENT-REPORTED OUTCOME DOMAINS FOR OSTEOARTHRITIS.  13:A312-A312. 2010
  • PMS52 PREFERENCES OVER BENEFITS AND RISKS ASSOCIATED WITH THE USE OF NSAIDS: EVIDENCE FROM PATIENTS DIAGNOSED WITH OSTEOARTHRITIS (OA) IN UK.  13:A312-A312. 2010
  • PMS68 PHYSICIANS' STATED PREFERENCES OVER BENEFITS AND RISKS ASSOCIATED WITH NSAID USE IN PATIENTS WITH OSTEOARTHRITIS IN UNITED KINGDOM.  13:A316-A316. 2010
  • CV1 PERIOPERATIVE BLOOD PRESSURE CONTROL DURING CARDIAC SURGERY REDUCES HOSPITALIZATION COSTS.  13:A11-A11. 2010
  • PCN110 HOW MUCH DO PATIENTS WITH RENAL CELL CARCINOMA (RCC) VALUE PROGRESSION FREE SURVIVAL IN MEDICAL DECISION MAKING?–RESULTS FROM A BENEFIT-RISK CONJOINT STUDY.  13:A44-A45. 2010
  • PCV110 DISCRIMINATORY POWER OF THE KCCQ IN ESTIMATING HEALTH UTILITIES IN HEART FAILURE PATIENTS.  13:A170-A170. 2010
  • PMC29 PATIENT PREFERENCE WEIGHTS FOR BENEFIT-RISK ANALYSIS: A STATIN CASE STUDY.  13:A19-A19. 2010
  • PSY48 THE VALUE TO PATIENTS OF TREATING PLAQUE PSORIASIS.  13:A214-A215. 2010
  • PSY55 IS HOSPITAL EXPERIENCE ASSOCIATED WITH BETTER IN-HOSPITAL OUTCOMES AMONG SICKLE CELL PATIENTS WITH ACUTE CHEST SYNDROME: RESULTS FROM A NATIONAL DATABASE.  13:A216-A216. 2010
  • LIVES WORTH LIVING: OLDER SMOKERS' STATED PREFERENCES FOR LONGEVITY.  12:A227-A228. 2009
  • PATIENT PREFERENCES FOR BENEFIT-RISK TRADEOFFS AMONG POST-TRANSPLANT OUTCOMES IN END-STAGE RENAL DISEASE.  12:A227-A227. 2009
  • PCV61 COST OF EXERCISE TRAINING AND ITS IMPACT ON MEDICAL RESOURCE USE AND COSTS: RESULTS OF HF-ACTION TRIAL.  12:A323-A323. 2009
  • PMC70 CLASSIFYING PATIENT REPORTED OUTCOMES: DEVELOPMENTS IN THE FIELD SUGGEST A NEW TAXONOMY.  12:A400-A400. 2009
  • PR4 LINEAR SCORING RULES FOR PATIENT REPORTED OUTCOMES AND PATIENT PREFERENCES.  12:A232-A232. 2009
  • UT3 HEALTHY-DAYS TIME EQUIVALENTS FOR OUTCOMES OF ACUTE ROTAVIRUS INFECTIONS.  12:A224-A224. 2009
  • Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis..  12:899-908. 2009
  • Can NICE Be Nicer? In a World of Budget Constraints There Are No Easy Solutions.  12:634-636. 2009
  • Nasty or Nice? A Perspective on the Use of Health Technology Assessment in the United Kingdom.  12:S8-S13. 2009
  • CO4 COMPARISON OF INPATIENT COST ESTIMATION METHODS: USING DATA FROM A CYSTIC FIBROSIS TRIAL.  12:A7-A7. 2009
  • ECONOMIC ANALYSIS OF ENDEAVOR VS. CYPHER STENTS: RESULTS FROM THE ENDEAVOR III TRIAL.  12:A152-A152. 2009
  • ECONOMIC ANALYSIS OF THE ENDEAVOR DRUG-ELUTING STENT VS. THE DRIVER BARE METAL STENT: RESULTS FROM THE ENDEAVOR II TRIAL.  12:A152-A152. 2009
  • MD2 RACIAL DISPARITIES IN ANTI-DEMENTIA MEDICATION, ANTIDEPRESSANT, AND ANTIPSYCHOTIC USE AMONG MEDICARE BENEFICIARIES WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIAS.  12:A12-A12. 2009
  • PCV58 TRIAL-BASED ECONOMIC EVALUATION ALONGSIDE THE TCYB (TAKE CONTROL OF YOUR BLOOD PRESSURE) TRIAL.  12:A152-A152. 2009
  • PDB10 A COMPARISON OF ECONOMIC OUTCOMES BETWEEN ADHERENT AND NONADHERENT PATIENTS TREATED WITH ORAL ANTIDIABETIC MEDICATIONS.  12:A98-A98. 2009
  • PMC62 ASSESSING THE QUALITY OF CONJOINT ANALYSIS APPLICATIONS IN HEALTH: A PILOT EVALUATION OF THE ISPOR CHECKLIST FOR GOOD RESEARCH PRACTICE IN CONJOINT ANALYSIS.  12:A31-A31. 2009
  • CV1 WHAT IS THE CLINICAL BENEFIT OF PREVENTING NON-FATAL MYOCARDIAL INFARCTIONS?.  11:A341-A342. 2008
  • PMC28 STATUS-QUO BIAS IN STATED-CHOICE STUDIES: IS IT REAL?.  11:A567-A568. 2008
  • IN1 C. ALBICANS AND C. GLABRATA BLOODSTREAM INFECTIONS IN ADULTS: OUTCOMES AND ASSOCIATED COSTS.  11:A24-A24. 2008
  • PCV65 CHANGE IN HEALTH-RELATED QUALITY OF LIFE FOLLOWING NON-FATAL CARDIOVASCULAR EVENTS IN POST-MYOCARDIAL INFARCTION PATIENTS.  11:A205-A206. 2008
  • PCV94 PREDICTING HIGH COSTS IN MEDICARE BENEFICIARIES WITH HEART FAILURE.  11:A215-A215. 2008
  • PCV97 IS THERE A LEARNING CURVE ASSOCIATED WITH EXERCISE TRAINING IN PATIENTS WITH HEART FAILURE?.  11:A215-A216. 2008
  • PDB56 PREFERENCES FOR ORAL ANTIDIABETIC AGENTS AMONG PEOPLE WITH TYPE 2 DIABETES.  11:A233-A233. 2008
  • PMH86 THE STANDARDS FOR BIPOLAR EXCELLENCE (STABLE) PROJECT: A BIPOLAR DISORDER QUALITY IMPROVEMENT INITIATIVE TO DEVELOP ANDVALIDATE EVIDENCE-BASED PERFORMANCE MEASURES FOR ENDORSEMENT BY THE NATIONAL QUALITY FORUM (NQF).  11:A135-A136. 2008
  • PND18 HIGHER INPATIENT COSTS AMONG PATIENTS WITH SUBARACHNOID HEMORRHAGE COMPLICATED BY VASOSPASM.  11:A142-A142. 2008
  • PRS26 PREFERENCES FOR ONSET OF EFFECT OF COMBINATION MAINTENANCE MEDICATION AMONG ASTHMA PATIENTS.  11:A277-A277. 2008
  • PUK14 INPATIENT COSTS AND CLINICAL OUTCOMES OF S. AUREUS BLOODSTREAM AND NON-BLOODSTREAM INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE: FINDINGS FROM A MULTI-CENTER TRIAL.  11:A304-A304. 2008
  • Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective?.  11:334-344. 2008
  • International price comparisons for novel and follow-on drugs..  10:510-511. 2007
  • PCN76 COMPARISON OF PHYSICIAN AND PATIENT PREFERENCES FOR COLORECTAL CANCER SCREENING USING A DISCRETE CHOICE EXPERIMENT.  10:A346-A346. 2007
  • PIN44 INCORPORATING PROBABILISTIC ATTRIBUTES IN A STATED-CHOICE RISK-BENEFIT SURVEY.  10:A449-A449. 2007
  • PR3 PATIENTS', PARENTS', AND PHYSICIANS' RISK-BENEFIT TRADE-OFF PREFERENCES FOR CROHN'S DISEASE TREATMENTS.  10:A225-A226. 2007
  • CN3 60-MONTH DATA FROM IRIS USED TO UPDATE ESTIMATES OF SURVIVAL AND COST-EFFECTIVENESS OF FIRST-LINE IMATINIB IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA.  10:A12-A12. 2007
  • OB2 THE COST OF THE METABOLIC SYNDROME IN THE ELDERLY: FINDINGS FROM THE CARDIOVASCULAR HEALTH STUDY.  10:A19-A19. 2007
  • PHM1 A COMPARISON OF INPATIENT OUTCOMES BETWEEN SICKLE CELL DISEASE AND NON-SICKLE CELL DISEASE PATIENTS UNDERGOING HIGH-VOLUME SURGICAL PROCEDURES.  10:A152-A153. 2007
  • PST5 PROMOTING THE IMPROVEMENT OF STROKE CARE AT THE STATE-LEVEL: CREATING A LEGISLATIVE POLICY REPORT LINKED TO AN EVIDENCE-BASED SIMULATION MODEL.  10:A182-A182. 2007
  • Age-specific impact of obesity on prevalence and costs of diabetes and dyslipidemia.  10. 2007
  • Measuring patient preferences for colorectal cancer screening using a choice-format survey..  10:415-430. 2007
  • PCV5 DRUG-ELUTING STENT USE IS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN LONG-TERM CLINICAL OUTCOMES.  9:A338-A338. 2006
  • PGI16 ARE ADULTS MORE AVERSE TO TREATMENT RISKS FOR THEIR CHILDREN THAN THEY ARE FOR THEMSELVES?.  9:A246-A246. 2006
  • PHM3 HEPARIN-RELATED THROMBOCYTOPENIA ASSOCIATED WITH MAJOR INCREASE IN HOSPITAL COSTS.  9:A248-A248. 2006
  • PIH20 CONJOINT-ANALYSIS QALYS FOR ACUTE CONDITIONS.  9:A258-A258. 2006
  • The return on investment in health care: from 1980 to 2000..  9:146-156. 2006
  • Analytic considerations in economic evaluations of multinational cardiovascular clinical trials..  9:281-291. 2006
  • Eliciting stated preferences for health-technology adoption criteria using paired comparisons and recommendation judgments..  9:303-311. 2006
  • PCN13 COST-EFFECTIVENESS OF HEPATIC ARTERY INFUSION FOR METASTATIC COLORECTAL CANCER (CALGB 9481).  8:A37-A37. 2005
  • PCV23 ECONOMIC EVALUATION OFVALSARTAN IN PATIENTS WITH CHRONIC HEART FAILURE IN THE HUNGARIAN HEALTH CARE SETTING.  8:A95-A95. 2005
  • QLI IS RELIEF WORTH THE RISK? RISK-BENEFIT PREFERENCES FOR TREATMENTS FORVASOMOTOR SYMPTOMS.  8:244-245. 2005
  • Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty..  8:572-580. 2005
  • Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy..  8:47-52. 2005
  • Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report..  8:521-533. 2005
  • The economic burden of anemia in cancer patients receiving chemotherapy..  8:149-156. 2005
  • CN3 COST-EFFECTIVENESS OF IMATINIB VERSUS INTERFERON (IFN-a) PLUS LOW-DOSE CYTARABINE (ARA-C) FOR NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) IN THE THE NETHERLANDS.  7:644-644. 2004
  • PIN21 COMPARISON OF 30-DAY DIRECT MEDICAL COSTS OF AZITHROMYCIN AND LEVOFLOXACIN FOR PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA.  7:357-357. 2004
  • Estimating a preference-based single index for the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) instrument from the SF-6D..  7:490-498. 2004
  • PCV37: BASELINE PREDICTORS OF ONE-YEAR COSTS AFTER ACUTE MYOCARDIAL INFARCTION IN THE ELDERLY.  6:320-320. 2003
  • PDB27: RISKING HEALTH TO AVOIDING INJECTIONS—STATED PREFERENCES OF TYPE 2 DIABETICS IN THE US AND CANADA.  6:337-337. 2003
  • PMD6: ESTIMATING THE TRAJECTORY-ADJUSTED IMPACT OF ACUTE EVENTS ON PATIENT-REPORTED OUTCOMES.  6:293-293. 2003
  • PNP14: COST OF MULTIPLE SCLEROSIS BY LEVEL OF DISABILITY.  6:276-276. 2003
  • PNP24: ESTIMATES AND PATTERNS OF HEALTHCARE EXPENDITURES AMONG INDIVIDUALS WITH BACK PAIN IN THE US.  6:280-280. 2003
  • When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision analysis..  6:542-550. 2003
  • PHP24 USE OF POLICY MODELING TO PROMOTE INFORMED DECISION MAKING: DEVELOPMENT AND APPLICATION OF THE CANADIAN STROKE POLICY MODEL.  5:473-473. 2002
  • Modeling for health care and other policy decisions: uses, roles, and validity..  5:62-63. 2002
  • CV1: ESTIMATING THE IMPACT OF ANTICOAGULATION QUALITY ON EVENT RATES.  4:403-404. 2001
  • WW14: MAKING MODELS BETTER.  4:193-194. 2001
  • Modeling choice behavior for new pharmaceutical products..  4:32-44. 2001
  • PCV1: THE ATRIAL FIBRILLATION ANTITHROMBOSIS MODEL (AFAM): A GENERAL-PURPOSE TOOL FOR ANALYSIS, POLICY-MAKING, AND EDUCATION.  3:309-310. 2000
  • COST-EFFECTIVENESS ANALYSIS OF THE ONCOTYPE DX BREAST RECURRENCE SCORE (R) TEST FOR HR+/HER2-EARLY-STAGE BREAST CANCER IN THE US 2022
  • DEVELOPMENT OF 'QUALITY OF CARE FOR PATIENTS WITH ADVANCED ILLNESSES (QCPAI)' INSTRUMENT FOR MEASURING THE QUALITY OF END-OF-LIFE CARE FROM PATIENTS' PERSPECTIVE 2022
  • QUALITY OF LIFE AND BURDEN ON INFANT AND CAREGIVER DUE TO LOWER RESPIRATORY TRACT INFECTION: A PILOT PROSPECTIVE OBSERVATIONAL STUDY IN THE DUKE UNIVERSITY HEALTH SYSTEM 2022
  • ROLE PREFERENCES IN MEDICAL DECISION MAKING: IMPLICATIONS FOR HEALTH PREFERENCE RESEARCH 2022
  • ANNUAL HEALTHCARE RESOURCE UTILIZATION AND COSTS IN US PATIENTS DIAGNOSED WITH RELAPSED ACUTE MYELOID LEUKEMIA 2021
  • VALUING HOPE WITH CANCER TREATMENTS INDEPENDENT OF SURVIVAL GAINS 2021
  • A COST-EFFECTIVENESS ANALYSIS OF REPOSITIONING INTERVALS FOR PRESSURE INJURY PREVENTION: AN ECONOMIC EVALUATION OF THE "TEAM-UP" CLINICAL TRIAL 2020
  • COMPARATIVE EFFECTIVENESS OF SYSTEMATIC THERAPIES FOR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER: A PARAMETRIC SURVIVAL NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS 2020
  • COST-EFFECTIVENESS ANALYSIS OF THE STEPPED EXERCISE PROGRAM FOR PATIENTS WITH KNEE OSTEOARTHRITIS (STEP-KOA) TRIAL 2020
  • DO MEN AND WOMEN INTERPRET THE KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE (KCCQ) DIFFERENTLY? 2020
  • ESTIMATING THE VALUE OF NURSING TIME TO REDUCE COSTS AND INCREASE QUALITY OF PRESSURE INJURY PREVENTION IN NURSING HOMES: A COST-EFFECTIVENESS ANALYSIS OF THE TEAM-UP CLINICAL TRIAL 2020
  • IS CURRENT TRIAL DATA SHARING STATUS CONDUCIVE FOR EVIDENCE GENERATION FOR PERSONALIZED MEDICINE: A FAILED ATTEMPT TO CONDUCT AN INDIVIDUAL PATIENT TRIAL DATA NETWORK META-ANALYSIS 2020
  • NOVEL PEANUT-ALLERGY DESENSITIZATION TREATMENTS: WHO IS LIKELY TO CHOOSE TREATMENT AND WHY 2020
  • ORAL NUTRITIONAL SUPPLEMENTATION CAN IMPROVE POSTOPERATIVE OUTCOMES FOR COLORECTAL SURGERY PATIENTS 2020
  • PATIENT PREFERENCES FOR MITRAL VALVE PROCEDURE-ASSOCIATED BENEFITS REVEAL GREATER RISK TOLERANCE AS HEART FAILURE SYMPTOMS WORSEN 2019
  • WOMEN'S PREFERENCES ON BENEFITS, RISKS, AND SIDE EFFECTS OF MAINTENANCE PARP INHIBITOR THERAPY IN OVARIAN CANCER 2019
  • PAM8 IMPACT OF PERIOPERATIVE NUTRITION ON HEALTH OUTCOMES IN ONCOLOGY PATIENTS UNDERGOING GASTROINTESTINAL SURGERIES 2019
  • PCN146 HEALTHCARE RESOURCE UTILIZATION & EXPENDITURES AMONG MEDICARE BENEFICIARIES NEWLY DIAGNOSED WITH PERIPHERAL T-CELL LYMPHOMA (PTCL): A RETROSPECTIVE CLAIMS ANALYSIS 2019
  • PCV97 ECONOMIC VALUE OF NON-VKA ORAL ANTICOAGULANTS (NOAC) IN NON-VALVULAR ATRIAL FIBRILLATION (NVAF): A LITERATURE REVIEW OF GLOBAL HEALTH TECHNOLOGY ASSESSMENTS (HTA) 2019
  • PMS17 ONE-YEAR HEALTHCARE UTILIZATION AND COSTS AFTER KNEE ARTHROPLASTY 2019
  • PNS232 ARE VIDEOS OR TEXT BETTER FOR DESCRIBING ATTRIBUTES IN STATED-PREFERENCE SURVEYS? SOME EXPERTS WILL BE SURPRISED 2019
  • PSU37 QUANTIFYING BENEFIT-RISK TRADEOFFS FOR SURGICAL OPTIONS IN LOW-RISK THYROID CANCER 2019
  • CV1 - A COST-EFFECTIVENESS ANALYSIS OF MULITI-GENE PHARMACOGENETIC TESTING IN ACUTE CORONARY SYNDROME PATIENTS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION 2018
  • PCN249 - CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) AND DRIVERS OF ANTIEMETIC PRESCRIBING: RESULTS OF A QUALITATIVE IN-PRACTICE STUDY OF CLINICIANS FROM VARIOUS SETTINGS 2018
  • PIN127 - HETEROGENEOUS PREFERENCES FOR HIV/AIDS COUNSELING AND TESTING AMONG TWO HIGH RISK POPULATIONS IN NORTHERN TANZANIA - RESULTS FROM A DISCRETE CHOICE EXPERIMENT 2018
  • PMD180 - THE VALUE TO WOMEN WITH OVARIAN CANCER OF GENE VARIANTS WITH KNOWN AND UNKNOWN SIGNIFICANCE: A DISCRETE CHOICE EXPERIMENT 2018
  • PP4 - ONE SIZE DOES NOT FIT ALL: HETEROGENEOUS PATIENT PREFERENCES AND TRADEOFFS FOR ANTIRETROVIRAL THERAPY - RESULTS OF A DISCRETE CHOICE EXPERIMENT 2018
  • PRM189 - SUBJECTIVE MEASURE MAY BE MORE SENSITIVE IN IDENTIFYING PROGNOSTIC FACTORS OF FUNCTIONAL OUTCOME AMONG OLDER ADULTS WITH SURGICALLY-TREATED HIP FRACTURE – FINDINGS FROM A SYSTEMATIC REVIEW 2018
  • Cost-Effectiveness Analysis of the Ageing-in-Place (Aip) Programme 2018
  • Challenges to Reducing Low-Value Care: Lessons Learned and Future Directions 2018
  • Patient Preferences for Health States Following Alternative Management Options for Ductal Carcinoma in Situ 2018
  • Something is Better Than Nothing: The Value of Active Intervention on Stated Preferences for Treatments to Delay Onset of Alzheimer’s Disease Symptoms 2018
  • Prioritizing Patient-Relevant Attributes of HIV Medications: A Mixed Methods Approach 2017
  • A SYSTEMATIC REVIEW OF THE ASSOCIATION BETWEEN OBESITY AND OUTCOME OF RHEUMATIC DISEASES 2017
  • ASSESSING THE FINANCIAL VALUE OF PATIENT ENGAGEMENT 2017
  • ASSOCIATION BETWEEN ACCESS TO HEALTH-PROMOTING FACILITIES AND PARTICIPATION IN CARDIOVASCULAR DISEASE (CVD) RISK SCREENING AMONG POPULATIONS WITH LOW SOCIOECONOMIC STATUS (SES) IN SINGAPORE 2017
  • ASSOCIATION OF OBESITY WITH PATIENT-REPORTED OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A CROSS-SECTIONAL STUDY IN AN URBAN ASIAN POPULATION 2017
  • EFFECTS ON COMPENSATING VARIATION OF NUMBER AND KIND OF COMPETING SUBSTITUTES IN DISCRETE-CHOICE EXPERIMENTS 2017
  • FACTORS OF CARDIOVASCULAR DISEASE RISK SCREENING UPTAKE AMONG POPULATIONS WITH LOW SOCIOECONOMIC STATUS: A SYSTEMATIC REVIEW 2017
  • Good Enough For Policy Work? Study-Design Challenges In Implementing Stated-Preference Methods For Complex Health-Care Technologies 2016
  • Heterogeneous Preferences For Delaying Onset Of Alzheimer’s Disease Among Older Adults In The Us 2016
  • Predicted Demand For A New Injectable Solution For Delivering Glaucoma Medicine 2016
  • Reliability and Validity of the Health Assessment Questionnaire (Haq) in Patients with Spondyloarthritis 2016
  • Reliability and Validity of the Short-Form 36 (SF-36) Health Survey in Patients with Spondyloarthritis 2016
  • CLINICAL IMPACT OF THE 21-GENE RS TEST WITHIN THE VETERANS HEALTH CARE ADMINISTRATION 2016
  • Comparative-Effectiveness Analysis of Uterusconserving Procedures for Uterine Fibroids Using a Linked Electronic Medical Record Claims Database 2016
  • Identifying And Valuing Patient Group Engagement Methods 2016
  • TASTE HETEROGENEITY OR SOMETHING ELSE? ANALYZING STATED BENEFIT-RISK TRADEOFF PREFERENCES FOR PSORIASIS TREATMENTS 2016
  • US PAYER NEEDS FOR VALUE DEMONSTRATION FOR IGG THERAPIES 2016
  • NADIA® Psa Slope Impacts Urologists’ Recommendations for Adjuvant Radiotherapy for Prostate Cancer Patients with High-Risk Pathology Following Radical Prostatectomy 2014
  • Relative Influence of Factors Determining a Woman’s Preference for Treatment Options in Ovarian Cancer: A Discrete Choice Experiment 2014
  • Treatment patterns, health care resource utilization and costs in united states patients diagnosed with chronic hepatitis c infection 2014
  • Use of PSA Slope to Guide Adjuvant Radiotherapy in Post-Prostatectomy Prostate Cancer has Potential to be Cost Effective 2014
  • Working title: Contraindications for HCV Therapy In United States patients with untreated chronic hepatitis C (CHC) 2014
  • PMH61 Effects of Lisdexamfetamine Dimesylate Augmentation on Functional Outcomes in Adults with Partially or Fully Remitted Major Depressive Disorder 2012
  • PCN122 DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE) 2010
  • PCN109 DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE) 2010
  • PCV111 ANALYZING THE RELATIONSHIP BETWEEN CHANGES IN PROS AND CLINICAL ENDPOINTS 2010
  • AR3 CAUSES AND EFFECTS OF SCENARIO REJECTION: STATED PREFERENCES FOR RHEUMATOID ARTHRITIS TREATMENTS 2007
  • PMC19 HOW GOOD IS GOOD ENOUGH? INTERNAL VALIDITY OF STATED PREFERENCES FOR DRUG THERAPIES 2007
  • PAR16 CAN OSTEOARTHRITIS PATIENTS EVALUATE TRADEOFFS BETWEEN NSAID RISKS AND BENEFITS? 2006
  • PR3 BIPOLAR PATIENTS' STATED THERAPY PREFERENCES AND LIKELY ADHERENCE 2005
  • PIN5 COST ANALYSIS OFA FEBRILE NEUTROPENIA ALGORITHM WITH RESPECT TO EMPIRICAL ANTIFUNGAL THERAPY IN ADULT HEMATOLOGY/ONCOLOGY PATIENTS 2005